908 Devices Q4 revenue beats on FTIR product strength

908 Devices

03/03/2026 12:08

Overview

Chemical analysis toolmaker's Q4 revenue rose 21%, beating analyst expectations

Net income for Q4 beat analyst expectations

Company achieved positive adjusted EBITDA in Q4

Outlook

908 Devices expects 2026 revenue between $64.5 mln and $67.5 mln, up 15%-20% from 2025

Result Drivers

FTIR PRODUCT REVENUE - Q4 revenue growth largely driven by increase in FTIR product sales

INSTALLED BASE EXPANSION - Installed base grew 24% year-over-year, supporting revenue growth

RECURRING REVENUE - Recurring revenue represented 32% of total revenues in the quarter, indicating strong customer retention

Company press release: ID:nBw1sXhpla

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Beat
$17.40 mln
$15.84 mln (4 Analysts)
Q4 Net Income
Beat
$4.20 mln
-$3.62 mln (3 Analysts)
Q4 Gross Profit
$9.20 mln
Q4 Operating Expenses
$6.10 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."

Wall Street's median 12-month price target for 908 Devices Inc is $10.00, about 51.3% above its March 2 closing price of $6.61

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)